Form 4: Labcorp COO Schroeder receives performance shares
Insider Ownership Change (Form 4)
Labcorp EVP and Diagnostics President Mark S. Schroeder reported net share acquisitions from 2023 performance awards on March 26, 2026, with tax withholdings at $268.38 per share.
Summary
- On 2026-03-26, Mark S. Schroeder (EVP, President Diagnostics & COO) acquired 9,304 and 2,968 Labcorp common shares at $0 pursuant to performance awards granted on 2023-02-07 and 2023-05-05.
- These awards relate to performance over the three-year period ended 2025-12-31.
- Shares withheld to satisfy tax obligations totaled 4,600 and 1,468 at $268.38 per share.
- Direct beneficial ownership after all transactions is 12,677.1426 shares.
- Form signed by attorney-in-fact on 2026-03-30.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine, neutral insider vesting event with a modest net increase in insider holdings and no broader financial or strategic implications.
Positives
- Performance-based equity vested and delivered 9,304 and 2,968 shares (gross) at $0, indicating long-term incentive alignment.
- Net increase in directly held shares of approximately 6,204 (12,272 vested less 6,068 withheld for taxes).
- No open-market sales; dispositions were solely for tax withholding.
Negatives
- Tax withholdings reduced the gross award by 6,068 shares at $268.38 per share.
- No open-market purchases to signal incremental confidence beyond equity vesting.
- No financial or operational metrics disclosed.
Future Outlook
No forward-looking statements or guidance provided.
Management Comments
- Shares acquired on 2026-03-26 pursuant to performance awards granted on 2023-02-07 and 2023-05-05 relating to performance during the three-year period ended 2025-12-31.
- Shares were withheld to satisfy tax withholding obligations at $268.38 per share.
Industry Context
StockSavvy.ai notes that three-year performance share vesting with tax withholding is standard across healthcare services and diagnostics peers, aligning executive incentives with multi-year outcomes; similar PSU/RSU structures are common at Quest Diagnostics (DGX), Thermo Fisher (TMO), and Hologic (HOLX).
Comparison to Industry Standards
- Equity vesting cadence: A three-year PSU cycle aligns with practices at Quest Diagnostics (DGX) and Thermo Fisher (TMO), where PSUs typically cliff-vest after 3 years based on TSR and financial metrics.
- Settlement mechanics: Tax withholding via share reduction at vest is standard across large-cap healthcare, mirroring common approaches at DGX and HOLX.
- Signal value: Absence of open-market buying is typical around vesting events industry-wide; insider buying used as a confidence signal is more notable when purchases are discretionary rather than tied to award schedules.
Stakeholder Impact
- Executive’s direct beneficial ownership stands at 12,677.1426 shares following the transactions.
- Dispositions were solely for tax withholding; no open-market sales occurred.
- No effects on customers, suppliers, or operations indicated.
Key Dates
| Date | Description |
|---|---|
| 2023-02-07 | Grant date of performance award referenced in note (1) |
| 2023-05-05 | Grant date of performance award referenced in note (3) |
| 2025-12-31 | End of three-year performance period for both awards |
| 2026-03-26 | Share acquisitions and tax withholdings executed |
| 2026-03-30 | Form signed by attorney-in-fact for Mark S. Schroeder |
Keywords
Labcorp, LH, Mark S. Schroeder, Form 4, insider transaction, performance award, PSU, executive compensation, stock withholding, beneficial ownership, diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.